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AbstrACt
Objectives To characterise serum creatinine and urinary 
protein testing in UK general practices from 2005 to 
2013 and to examine how the frequency of testing varies 
across demographic factors, with the presence of chronic 
conditions and with the prescribing of drugs for which 
kidney function monitoring is recommended.
Design Retrospective open cohort study.
setting Routinely collected data from 630 UK general 
practices contributing to the Clinical Practice Research 
Datalink.
Participants 4 573 275 patients aged over 18 years 
registered at up-to-standard practices between 1 April 
2005 and 31 March 2013. At study entry, no patients were 
kidney transplant donors or recipients, pregnant or on 
dialysis.
Primary outcome measures The rate of serum 
creatinine and urinary protein testing per year and the 
percentage of patients with isolated and repeated testing 
per year.
results The rate of serum creatinine testing increased 
linearly across all age groups. The rate of proteinuria 
testing increased sharply in the 2009–2010 financial year 
but only for patients aged 60 years or over. For patients 
with established chronic kidney disease (CKD), creatinine 
testing increased rapidly in 2006–2007 and 2007–2008, 
and proteinuria testing in 2009–2010, reflecting the 
introduction of Quality and Outcomes Framework 
indicators. In adjusted analyses, CKD Read codes were 
associated with up to a twofold increase in the rate of 
serum creatinine testing, while other chronic conditions 
and potentially nephrotoxic drugs were associated with up 
to a sixfold increase. Regional variation in serum creatinine 
testing reflected country boundaries.
Conclusions Over a nine-year period, there have been 
increases in the numbers of patients having kidney 
function tests annually and in the frequency of testing. 
Changes in the recommended management of CKD in 
primary care were the primary determinant, and increases 
persist even after controlling for demographic and patient-
level factors. Future studies should address whether 
increased testing has led to better outcomes.
IntrODuCtIOn
Kidney function testing in primary care is 
used to diagnose and monitor chronic kidney 
disease (CKD). Testing is recommended at 
baseline and after initiation of some drugs 
such as antihypertensives.1 Kidney function 
is usually tested by measuring serum creati-
nine, and screening for glomerular disease is 
undertaken by measuring urine albumin or 
protein concentrations.
In 2002, the Kidney Disease Outcomes and 
Quality Initiative (K/DOQI) published clin-
ical guidelines advocating that CKD be cate-
gorised into five stages.2 Two years later, these 
stages were adopted by the UK Quality and 
Outcomes Framework (QOF), which is a set 
of business rules for primary care that include 
financial incentives to regularly monitor and 
test certain subsets of patients and to record 
their data.3 The 2006–2007 financial year saw 
an extension to QOF that required general 
practitioners to maintain a register of patients 
with CKD stages 3–5.4 In 2008, the National 
Institute for Health and Care Excellence 
(NICE) recommended monitoring estimated 
glomerular filtration rate (eGFR) levels in 
high-risk patients.5 Then in the 2009–2010 
financial year, a further QOF extension incen-
tivised monitoring urinary markers of kidney 
disease (such as proteinuria) in patients on 
strengths and limitations of this study
 ► To date, this is the largest population study of trends 
in renal function testing in primary care.
 ► The data source did not permit us to ascertain why a 
kidney function test was performed.
 ► The transitioning of ‘high risk’ patients from primary 
to secondary care means the estimates in this study 
may be liable to underestimate the amount of test-
ing performed in certain patient subgroups.
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the CKD register.6 Current NICE recommendations on 
the frequency of testing are based on the underlying 
cause of CKD, previous test results, comorbidities and 
the treatments being used. Monitoring is recommended 
annually in patients with mild to moderate reductions in 
kidney function and every three months in patients with 
more advanced disease.1
National rates of kidney function testing and potential 
differences between different populations have not been 
characterised. In contrast, rates of kidney function testing 
in patients with diabetes have been well documented. A 
cohort study of adults with diabetes showed that under 
13% had incomplete CKD screening, and just 4.4% had 
no serum creatinine measurement on record in the two 
and half years before the start of the study, whereas the 
albumin-creatinine ratio (ACR) was not monitored in 
37% during the same period.7 Similarly, high frequencies 
of serum creatinine testing have been observed among 
patients with diabetes in studies looking at individual 
health regions, but with more variable levels of recording 
in patients without diabetes across different ages, genders 
and ethnic groups.8
There has been a dramatic increase in the use of labo-
ratory testing over recent decades, particularly repeated 
testing or monitoring.9 10 However, it is unclear whether 
this increase is appropriate and consistent with guide-
line recommendations or whether it represents overt-
esting. Appropriate testing of kidney function might be 
of value in planning management to slow the progression 
of the disease and, therefore, lead to tangible patient 
benefit. However, overuse of tests provides little patient 
benefit and adds to the financial burden of healthcare 
systems. A recent meta-analysis of the use of laboratory 
tests during the last 15 years showed that underuse of 
high-volume tests (such as creatinine) was more likely 
than overuse.11 A cross-sectional survey of US physicians’ 
patterns of care in patients with CKD showed that 85% 
of physicians recommended one additional test, which 
was not recommended in the Kidney Disease Improving 
Global Outcomes (KDIGO) guidelines.12 These tests 
were most likely to be magnetic resonance angiography 
of renal arteries or serum protein electrophoresis, rather 
than blood or urinary measurements.13 It is, of course, 
possible that overuse and underuse may coexist, with 
some patients receiving more tests than indicated and 
other patients not receiving tests warranted by their clin-
ical history, recent health and age.
Currently, the UK is the only nationalised and publicly 
funded health service that has introduced financial incen-
tives to improve the quality of healthcare for patients 
with CKD. National guidelines in other countries also 
recommend quality standards for CKD care, including 
diagnosis, monitoring of renal function and control of 
cardiovascular risk factors.14 However, guideline bodies 
outside the UK have stopped short of implementing 
financial incentives for CKD care, and therefore, studying 
the impact of QOF in the UK can inform international 
efforts to improve outcomes for patients with CKD.
The aim of this study is to describe rates of kidney 
function testing since the introduction of the QOF in 
UK general practice. Specifically, we have examined 
the numbers of serum creatinine and proteinuria tests 
requested in each financial year during the nine years 
from 2005 to 2013 by: age category, gender, ethnicity, 
index of multiple deprivation (IMD), Strategic Health 
Authority (SHA), CKD stage, the presence or absence 
of major comorbidities (such as diabetes, hypertension, 
cardiovascular disease and atrial fibrillation) and the 
prescription of nephrotoxic drugs.
MethODs
Data
We used the Clinical Practice Research Datalink (CPRD)15 
to construct an open cohort study of adults (≥18 years 
of age) registered at UK general practices whose data 
quality was deemed to be ‘up-to-standard’, that is, the 
data committed by general practices has reached a stan-
dard suitable for research (based on a CPRD algorithm 
that primarily focusses on death recording and gaps in 
the data).
study period
We selected a start date of 1 April 2005, which postdated 
the publication of the K/DOQI guidelines for classifica-
tion of CKD in 2002,2 and the introduction of QOF in UK 
primary care in 2004.3 The study end date was 31 March 
2013.
Inclusion and exclusion criteria
Eligible patients had to have been registered with their 
practice for a minimum of 12 months before their study 
entry to ensure adequate recording of baseline covari-
ates. The study entry date was defined as the latest of 
either the study start date (1 April 2005) or the date of 
the patient’s current registration date +12 months. We 
excluded patients who were living kidney donors, had a 
renal transplant, ever underwent dialysis or women who 
were pregnant in the 12 months prior to study entry. 
Follow-up ended at the study end date, unless preceded 
by the patient’s death, transfer out of CPRD, the last avail-
able linked data, or (where applicable) pregnancy, renal 
transplantation/donation or dialysis. For any given finan-
cial year, patient records were excluded if their data were 
incomplete/censored.
Outcomes
A serum creatinine test was deemed to have occurred 
when a patient test record contained a valid date, an 
entity type associated with serum creatinine testing or 
blood/serum biochemistry and a Read code for serum 
creatinine testing (online supplementary table 1).
A proteinuria test was deemed to have occurred when 
a patient test record contained a valid date, an entity type 
associated with urine biochemistry tests and a Read code 
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for albuminuria or proteinuria testing (online supple-
mentary table 2).
A protocol-specified additional analysis, of Read codes 
for kidney function tests that could not be identified as 
serum creatinine or proteinuria, could not be carried out 
because use of these codes was highly heterogeneous by 
practice, with some practices making extensive use and 
other no use of such codes.
Subsequent tests recorded per patient on the same 
day were discarded, as these appeared to either be 
multiple abstractions from the same sample or data entry 
anomalies.
Variables
Nominal CKD stage was identified by Read codes 
(online supplementary table 1). Albuminuria status was 
derived using either ACR or protein:creatinine ratio 
(PCR). When these were unavailable, raw albumin excre-
tion rate or protein excretion rate were used. Normoal-
buminuria (albuminuria stage A1) was defined as <3 mg/
mmol, microalbuminuria (albuminuria stage A2) was 
defined as 3–30 mg/mmol and macroalbuminuria (albu-
minuria stage A3) as >30 mg/mmol, in accordance with 
the 2012 KDIGO guidelines for evaluation and manage-
ment of CKD.12 eGFR was calculated using the four-part 
Modification of Diet in Renal Disease (MDRD) equation 
based on recorded values of serum creatinine, sex, age 
at test and ethnicity.16 The four-part MDRD equation 
was used in place of the Chronic Kidney Disease Epide-
miology Collaboration (CKD-EPI) equation,17 more 
recently advocated by NICE, as this was the equation that 
would predominantly have been used to monitor patients 
during the follow-up period.
Prevalence data for the comorbidities of: atrial fibril-
lation, cancer, diabetes, heart failure, hypertension, isch-
aemic heart disease, peripheral vascular disease, stroke 
or transient ischaemic attack and thyroid disease were 
assessed by the presence of diagnostic Read codes in 
patient clinical records.
Pharmacotherapies that were either nephrotoxic, 
excreted by the kidneys or that affected serum potassium 
were established through consensus between the general 
practitioners/pharmacologists (JA, CAO and CJT). 
These consisted of: ACE inhibitors, angiotensin receptor 
blockers, amiodarone/dronedarone, digoxin, diuretics, 
gold, immunosuppressants, lithium, mesalazine, non-ste-
roidal anti-inflammatory drugs and oral anticoagulants 
(OACs).
Patient demographic data were also extracted, including 
age, gender, ethnicity, deprivation and region. Within 
these variables, age was categorised into seven levels 
(18–39, 40–49, 50–59, 60–69, 70–79, 80–89 and 90+ years), 
ethnicity was divided into six categories (‘white’, ‘Asian’, 
‘black’, ‘mixed’, ‘other’ or ‘missing’), deprivation was 
categorised into six levels (representing quintiles of IMD 
data plus a ‘missing’ level) and region was divided into 13 
categories (aligning with the 10 SHAs of England and the 
countries of Northern Ireland, Scotland and Wales).
Analyses
Trends across kidney disease categorisations
Adherence to the most current NICE guidelines1 was eval-
uated by stratifying crude rates of serum creatinine and 
proteinuria testing (herein jointly referred to as ‘kidney 
function testing’) by CKD stage, and eGFR and albumin-
uria categories. We present these rates as tile and line 
plots.
Trends over time
We calculated crude rates of kidney function tests, strati-
fied by financial year, and further stratified by CKD stage, 
demographic factors (such as age, ethnicity and depriva-
tion), the presence of various comorbidities and concur-
rent prescriptions for nephrotoxic drugs. We present 
the percentage of patients with 1, 2, 3, 4 and >4 tests per 
financial year for serum creatinine and urinary albumin/
protein as bar plots.
Factors associated with kidney function testing
We examined factors associated with serum creatinine 
testing in CPRD. We used a mixed effects Poisson model 
implemented as a negative binomial regression model18 to 
assess the relationship between demographic factors, the 
presence of markers for CKD and other chronic condi-
tions and indicators of drug therapy. We fitted age and 
year of entry into the study as categorical factors in order 
to model non-linear associations. The presence of Read 
codes for CKD was used as markers of kidney disease. 
We studied 13 geographic regions corresponding to the 
SHAs of England and the countries of Scotland, Northern 
Ireland and Wales. The model was adjusted for the pres-
ence of chronic conditions and medications. These were 
added to the models as binary covariates if a Read code 
or Gemscript code was present within the eligible data 
preceding the study entry date for that patient. The 
outcome of the model was the number of serum creatinine 
tests on record following study entry with the log person-
years of follow-up used as the offset term. The model, 
therefore, estimates the natural log rates of serum creat-
inine testing, and covariate effects are log incidence rate 
ratios (IRRs). We have presented results from unadjusted, 
that is, univariable, minimally adjusted, that is, adjusted 
for gender, age, ethnicity, deprivation, region and year of 
entry and fully adjusted, that is, adjusted for all extracted 
variables, models on a natural scale, as IRRs with 95% CIs.
Statistical software and packages
All analyses were conducted in R (V.3.5.1).19 Plots were 
produced using the ggplot2 package.20 Crude rates and 
their 95% CIs were calculated via the skewness-corrected 
asymptotic score method21 implemented in the scaspci() 
function of the ratesci package.22 Negative binomial 
models were fit using the  glm. nb() function of the MASS 
package.23
Patient and public involvement
This project has been reviewed by individuals with long-
term conditions that require frequent monitoring, as 
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well as nurse practitioners and general practice commis-
sioners. Patient and public involvement members have 
also been invited to the steering and senior management 
groups. A patient and public involvement expert was also 
involved as a strategic consultant in a programme of work 
including this project.
results
baseline demographics
We identified 4 573 275 patients from 630 practices 
with 26 496 643 person-years of eligible follow-up data, 
containing a total of 15 049 063 serum creatinine tests and 
9 95 524 proteinuria tests. The median length of follow-up 
was 6.1 (IQR 3.5–9.0) years. The cohort comprised 49.7% 
men and 50.3% women. The median (IQR) age was 46 
(34–61) years (table 1).
trends across kidney disease categorisations
CKD categories
When categorising kidney disease according to CKD 
stages, the highest rates of kidney function testing were 
found in patients with CKD stage 4 (figure 1). The lowest 
rates of testing were observed in patients without a Read 
code for CKD; however, such patients were still receiving 
roughly one serum creatinine test every 2 years and one 
proteinuria test every 9 years. Rates of serum creatinine 
testing were roughly in line with NICE guidelines for CKD 
stages 1–4 but fell below recommendation in stage 5.1
Estimated glomerular filtration rate and albuminuria categories
The rates of serum creatinine testing observed in the data 
were higher than those advocated by NICE1 and KDIGO24 
in all eGFR–albuminuria subcategories (figure 2). The 
highest rates of serum creatinine testing were in patients 
with eGFR stage G5. Patterns of proteinuria testing were 
less consistent, with patients with eGFR stage G5 or albu-
minuria stage A3 both exhibiting high rates of proteinuria 
testing. Rates of kidney function testing were generally 
higher than expected for individuals with either no eGFR 
or proteinuria stage assigned. For instance, patients with 
no assignable eGFR category and normal (A1) albu-
minuria levels were still receiving 0.84 (95% CI 0.84 to 
0.85) serum creatinine tests per year, while patients with 
no assignable albuminuria level and normal (G1) eGFR 
levels were still receiving 0.25 (95% CI 0.25 to 0.25) 
proteinuria tests per year.
trends over time
Trends across CKD categories
Figure 3 shows trends in serum creatinine (left panel) and 
urinary protein testing (right panel), stratified by stage of 
CKD for the same period. Rates of kidney function testing 
increased with CKD stage up to stage 4, though rates in 
CKD stage 5 were lower or similar to rates in CKD stage 4. 
For patients in stages 2–5, rapid increases in the number 
of serum creatinine tests coincided with the inclusion 
of CKD management in QOF in 2006–20074 and then 
stabilised after 2007–2008. Sharp increases in proteinuria 
testing for patients with CKD stages 2–5 also coincided 
with the incorporation of proteinuria testing into QOF 
guidelines for the monitoring of CKD in 2009–2010.6
General trends in testing
The percentage of patients receiving kidney function tests 
has been steadily increasing year on year (figure 4). In 
the 2005–2006 financial year, 27.2% of patients received 
a serum creatinine test, while 7.5% of patients received 
a proteinuria test. In the 2012–2013 financial year, 
these figures were 38.1% and 11.8%, respectively. These 
increases appear to be driven by increases in the number 
of patients with isolated kidney function testing, that is, 
patients receiving one test per year, which for serum creat-
inine tests increased from 18.5% in 2005–2006 to 25.2% 
in 2012–2013. For proteinuria testing, isolated testing 
increased from 5.6% in 2005–2006 to 9.1% in 2012–2013. 
In the same time period, the percentage of patients with 
repeated serum creatinine testing, that is, two or more 
tests per year, increased from 8.7% to 12.9%, while the 
percentage of patients with repeated proteinuria testing 
increased from 2.0% to 2.7%.
trends in testing across demographic data
figure 5 shows the yearly trend in testing for serum creat-
inine (left panel) stratified by age and the equivalent 
trends in urinary protein tests (right panel). In general, 
rates of testing were higher with higher age, up to age 
80–89 years, but note that rates in the 90+ years age group 
are not the highest. Serum creatinine test rates increased 
approximately linearly over time within each decile of 
age. In contrast, urinary protein test rates were constant 
over time in age groups less than 60 years and increased 
over time for patients over 60 years of age, with a sharp 
increase in the year 2009–2010.
Differences between the rates of kidney function 
testing were much lower when stratifying by gender 
(online supplementary figure 1), ethnicity (online supple-
mentary figure 2), IMD quintile (online supplementary 
figure 3) and geographic region (online supplementary 
figure 4). Testing was marginally higher in women than 
men for both serum creatinine and proteinuria tests, with 
rate differences of roughly 0.1 tests per year and 0.02 
tests per year, respectively. These differences remained 
relatively constant throughout the follow-up period. 
Testing remained higher in patients coded in the CPRD 
as white or mixed ethnicity, with patients of black or Asian 
ethnicity having lower rates of testing. A similar pattern 
was found in proteinuria testing. Rates of kidney function 
testing were similar when stratifying by IMD quintile, with 
rates being lowest in the lowest (most affluent) IMD quin-
tile, for both markers of kidney function. Stratification 
by SHA region resulted in slightly larger differences in 
testing rates of up to 0.25 tests per year for serum creat-
inine and 0.14 tests per year for proteinuria. London 
demonstrated the lowest rates of kidney function testing 
for the majority of the study observation period. The 
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Table 1 Characteristics of the cohort at study entry (note: missing categories omitted)
Characteristic Female (n=2 279 097) Male (n=2 294 178) Everyone (n=4 573 275)
Age (years), n (%)
  18–39 807 015 (35.4) 904 018 (39.4) 1 711 033 (37.4)
  40–49 437 734 (19.2) 475 130 (20.7) 912 864 (20.0)
  50–59 370 235 (16.2) 379 112 (16.5) 749 347 (16.4)
  60–69 286 951 (12.6) 278 903 (12.2) 565 854 (12.4)
  70–79 212 826 (9.3) 174 193 (7.6) 387 019 (8.5)
  80–89 132 990 (5.8) 73 456 (3.2) 206 446 (4.5)
  ≥90 31 346 (1.4) 9366 (0.4) 40 712 (0.9)
Ethnicity, n (%)
  White 512 088 (22.5) 441 467 (19.2) 953 555 (20.9)
  Asian 42 888 (1.9) 43 623 (1.9) 86 511 (1.9)
  Black 19 819 (0.9) 17 302 (0.8) 37 121 (0.8)
  Mixed 316 792 (13.9) 303 891 (13.2) 620 683 (13.6)
  Other 13 933 (0.6) 14 310 (0.6) 28 243 (0.6)
Index of multiple deprivation, n (%)
  1 (least deprived) 334 473 (14.7) 337 305 (14.7) 671 778 (14.7)
  2 340 977 (15.0) 337 861 (14.7) 678 838 (14.8)
  3 293 127 (12.9) 294 250 (12.8) 587 377 (12.8)
  4 269 680 (11.8) 277 279 (12.1) 546 959 (12.0)
  5 (most deprived) 206 571 (9.1) 217 148 (9.5) 423 719 (9.3)
Chronic kidney disease stage, n (%)
  1 699 (0.0) 608 (0.0) 1307 (0.0)
  2 2512 (0.1) 2009 (0.1) 4521 (0.1)
  3 8149 (0.4) 4760 (0.2) 12 909 (0.3)
  4 687 (0.0) 459 (0.0) 1146 (0.0)
  5 73 (0.0) 75 (0.0) 148 (0.0)
Estimated glomerular filtration rate (mL/min/1.73 m2), n (%)
  ≥90 142 918 (6.3) 154 064 (6.7) 296 982 (6.5)
  60–89 512 731 (22.5) 459 469 (20.0) 972 200 (21.3)
  45–59 188 796 (8.3) 95 043 (4.1) 283 839 (6.2)
  30–44 52 765 (2.3) 23 242 (1.0) 76 007 (1.7)
  15–29 10 543 (0.5) 5782 (0.3) 16 325 (0.4)
  <15 833 (0.0) 480 (0.0) 1313 (0.0)
Albuminuria (mg/mmol), n (%)
  <3.0 39 442 (1.7) 42 665 (1.9) 82 107 (1.8)
  3–30 11 978 (0.5) 14 489 (0.6) 26 467 (0.6)
  >30 3096 (0.1) 3757 (0.2) 6853 (0.1)
Comorbidities, n (%)
  Atrial fibrillation 37 041 (1.6) 28 662 (1.2) 65 703 (1.4)
  Cancer 44 136 (1.9) 52 068 (2.3) 96 204 (2.1)
  Diabetes 267 791 (11.7) 238 922 (10.4) 506 713 (11.1)
  Heart failure 12 692 (0.6) 12 964 (0.6) 25 656 (0.6)
  Hypertension 21 381 (0.9) 21 497 (0.9) 42 878 (0.9)
  Ischaemic heart disease 49 227 (2.2) 59 621 (2.6) 1 08 848 (2.4)
  Peripheral vascular disease 19 153 (0.8) 21 166 (0.9) 40 319 (0.9)
  Stroke/transient ischaemic attack 21 988 (1.0) 21 774 (0.9) 43 762 (1.0)
  Thyroid disease 73 289 (3.2) 16 009 (0.7) 89 298 (2.0)
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highest rates of serum creatinine testing were initially 
seen in North East England, being surpassed by Northern 
Ireland in 2007–2008. Rates of serum creatinine testing 
were initially lowest in Scotland and London, until 
2010–2011, where rates of testing in Scotland increased. 
Conversely, the highest rates of proteinuria testing were 
present in the English East Midlands.
Trends in testing across comorbidities and pharmacotherapies
For all evaluated comorbidities, rates of kidney function 
testing were elevated when compared with a population 
for whom these comorbidities were absent (figure 6). 
Testing appears to have increased across all comorbidi-
ties with time, with the exception of diabetes, where the 
rate of testing appears to have decreased. The highest 
rates of serum creatinine testing were present in patients 
with heart failure and diabetes; however, all comorbidi-
ties were associated with at least one serum creatinine test 
per year by 2007–2008. The highest rates of proteinuria 
testing were present in patients with diabetes.
Across all evaluated pharmacotherapies, rates of kidney 
function testing were higher than in patients for whom 
prescriptions of these therapies were absent (figure 7). 
Rates of kidney function testing were relatively stable 
across time for most comorbidities with a few notable 
exceptions. For patients receiving prescriptions for gold, 
methotrexate or other immunosuppressants, serum 
creatinine testing appears to have increased with time. 
Proteinuria testing was elevated in patients prescribed 
Figure 1 Rates of kidney function testing (per year), stratified by CKD stage. CKD, chronic kidney disease.
Figure 2 Rates of kidney function testing (per year), stratified by eGFR and albuminuria categories. eGFR, estimated 
glomerular filtration rate.
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gold but was generally less than 0.5 tests/year for all other 
pharmacotherapies.
Factors associated with serum creatinine testing
The presence of a Read code for CKD was inde-
pendently associated with more frequent serum 
creatinine testing in primary care, with stage 4 CKD 
conferring the highest rates of testing (table 2). 
Testing frequency increased with age up to a peak 
at ages 80–89 years. Variation in testing between the 
SHA regions of England was quite low, with the excep-
tion of the North East and the South West, where the 
rates of testing were roughly 20% higher than that 
of London. Rates in Northern Ireland, Scotland and 
Wales were 21%–48% greater than those of London, 
possibly reflecting differences in clinical guide-
lines between England and other countries. In our 
adjusted model of testing frequency, the extent of 
testing in men and women differed by 14% IRR 1.14 
Figure 3 Rates of kidney function testing per financial year, stratified by CKD stage. CKD, chronic kidney disease; QOF, 
Quality and Outcomes Framework.
Figure 4 Percentage of patients that have had 1, 2, 3, 4 or more than four kidney function tests per financial 
year. NSAIDs, non-steroidal anti-inflammatory drugs; OACs, oral anticoagulants.
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(95% CI 1.14 to 1.14). All assessed comorbidities were 
significantly associated with elevated rates of serum 
creatinine testing with the exception of atrial fibrilla-
tion. With the exception of ethambutol, for all anal-
ysed pharmacotherapies, serum creatinine testing 
increased independently of other factors and was 
most marked in patients taking methotrexate, other 
immunosuppressants, gold and lithium.
DIsCussIOn
Key results
This is the first study to evaluate the rates of kidney func-
tion testing over a 9-year period following the introduc-
tion of the QOF in a large UK primary care database. Over 
the course of this study, rates of serum creatinine and 
proteinuria testing increased by 40% and 36%, respec-
tively, and by 2012–2013 almost 4 in every 10 people were 
Figure 5 Rates of kidney function testing per financial year, stratified by age category. QOF, Quality and Outcomes Framework.
Figure 6 Rates of kidney function testing per financial year, stratified by comorbidity. AFib, atrial fibrillation; HF, eart failure; 
HTN, hypertension; IHD, ischaemic heart disease; PVD, peripheral vascular disease; QOF, Quality and Outcomes Framework; 
TIA, transient ischaemic attack; THY, thyroid.
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receiving at least one serum creatinine test per year and 
over one in every 10 people were receiving at least one 
proteinuria test per year.
Across most strata evaluated, rates of kidney func-
tion testing appear to have either remained constant 
or increased with time. One notable exception to this 
was diabetes, where rates appear to have decreased 
with time. Women appear to be tested more than men, 
receiving roughly an extra 0.1 serum creatinine tests per 
year and an extra 0.02 proteinuria tests per year. This 
may be because women are more likely to schedule and 
attend appointments in primary care, as evidenced by 
a UK national study of patient factors associated with 
missed appointments.25 When stratifying by age, rates 
of kidney function testing increased between succes-
sive age categories up to age 80–89 years, with patients 
aged ≥90 years typically having lower rates of testing than 
patients aged 70–79 years. Serum creatinine and urinary 
protein testing have both increased across all ethnic 
groups, but patients of white and mixed ethnicities still 
have higher rates of testing than patients of black and 
Asian ethnicity. Stratification by IMD quintile demon-
strated minimal differences in testing rates. Conversely, 
stratification by comorbidity revealed the highest rates 
of both serum creatinine and proteinuria testing to be 
present in patients with heart failure or diabetes. Creat-
inine testing is undertaken in the primary care prac-
tice in the UK, rather than in a separate facility, and 
therefore, creatinine testing is sensitive to factors that 
influence practice attendance. However, some patients 
with diabetes will be managed by specialists as part of 
an outpatient hospital service and will have blood tests 
requested and taken at the hospital. These blood tests 
will not be sent to primary care electronic health records 
and will not appear in CPRD. The smaller rate of testing 
seen in this database for patients with diabetes may there-
fore not reflect deficiencies in overall care, but simply 
the fact that care is shared with the hospital for some 
of those patients. Stratification by concomitant pharma-
cotherapy revealed the highest rates of kidney function 
testing to be present in patients prescribed gold. Serum 
creatinine testing was also more frequent in patients 
prescribed immunosuppressants.
The effects of pay-for-performance indicators are 
visible in most plots present in this paper with notice-
able increases in the rates of serum creatinine testing 
in 2006–2007 and of proteinuria testing in 2009–2010. 
The former of these coincided with the requirement 
that general practices maintain a register of patients 
with CKD stages 3–5,4 while the latter coincided with 
the inclusion of the monitoring of secondary markers 
of kidney disease via ACR and PCR tests in patients on 
the CKD register.5 There was no obvious impact in any 
of the plots from the 2008–2009 NICE guidelines that 
recommended monitoring eGFR levels in high-risk 
patients.5
Frequency of serum creatinine testing was strongly 
associated with increasing age and the presence of a Read 
code for CKD in adjusted analyses. Testing frequency was 
also independently associated with chronic conditions 
and prescription of potentially nephrotoxic drugs but has 
risen year on year, even after accounting for age, chronic 
conditions and prescription of drugs that require moni-
toring of kidney function.
Figure 7 Rates of kidney function testing per financial year, stratified by concomitant pharmacotherapy. ACE-is, ACE 
inhibitors; ARBs, angiotensin II receptor blockers; Darones, amiodarone or dronedarone; Immuno, other (non-methotrexate) 
immunosuppressants; NSAIDs, non-steroidal anti-inflammatory drugs; OACs, oral anticoagulants; QOF, Quality and Outcomes 
Framework.
 o
n
 4 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028062 on 12 June 2019. Downloaded from 
10 Feakins B, et al. BMJ Open 2019;9:e028062. doi:10.1136/bmjopen-2018-028062
Open access 
Table 2 Results of regression models describing the demographic characteristics, the presence/absence of chronic 
conditions and drug prescription and associations with the frequency of serum creatinine testing in primary care
Characteristic Univariable IRR (95% CI) Minimally adjusted IRR (95% CI) Fully adjusted IRR (95% CI)
Gender
  Female 1.20 (1.20 to 1.21) 1.18 (1.18 to 1.18) 1.14 (1.14 to 1.14)
Age (years)
  40–49 2.09 (2.08 to 2.10) 2.10 (2.09 to 2.11) 1.92 (1.91 to 1.92)
  50–59 3.50 (3.49 to 3.51) 3.53 (3.52 to 3.54) 2.87 (2.86 to 2.88)
  60–69 5.38 (5.36 to 5.40) 5.39 (5.37 to 5.41) 3.94 (3.93 to 3.96)
  70–79 7.25 (7.22 to 7.27) 7.23 (7.20 to 7.26) 4.83 (4.81 to 4.85)
  80–89 7.57 (7.53 to 7.61) 7.47 (7.43 to 7.51) 4.86 (4.83 to 4.88)
  ≥90 6.17 (6.10 to 6.25) 5.94 (5.87 to 6.01) 4.05 (4.00 to 4.10)
Ethnicity
  Asian 0.78 (0.77 to 0.79) 1.25 (1.24 to 1.27) 1.23 (1.22 to 1.24)
  Black 0.77 (0.76 to 0.78) 1.19 (1.18 to 1.21) 1.16 (1.14 to 1.17)
  Mixed 0.96 (0.96 to 0.97) 1.00 (1.00 to 1.01) 1.00 (1.00 to 1.00)
  Other 0.71 (0.69 to 0.72) 1.05 (1.03 to 1.06) 1.04 (1.02 to 1.05)
  Not recorded 0.83 (0.83 to 0.83) 0.84 (0.84 to 0.84) 0.84 (0.84 to 0.84)
Index of multiple deprivation
  2 1.07 (1.06 to 1.07) 1.04 (1.04 to 1.05) 1.03 (1.02 to 1.03)
  3 1.07 (1.06 to 1.07) 1.07 (1.06 to 1.07) 1.04 (1.04 to 1.04)
  4 1.03 (1.03 to 1.04) 1.11 (1.11 to 1.12) 1.08 (1.07 to 1.08)
  5 (most deprived) 1.04 (1.03 to 1.04) 1.14 (1.13 to 1.14) 1.09 (1.08 to 1.09)
  Not recorded 1.05 (1.05 to 1.05) 1.07 (1.07 to 1.08) 1.03 (1.03 to 1.04)
Year of study entry
  2006 0.72 (0.71 to 0.72) 0.96 (0.95 to 0.96) 1.08 (1.08 to 1.09)
  2007 0.78 (0.77 to 0.78) 0.96 (0.95 to 0.96) 1.10 (1.09 to 1.10)
  2008 0.81 (0.80 to 0.81) 0.99 (0.98 to 1.00) 1.13 (1.13 to 1.14)
  2009 0.77 (0.76 to 0.78) 1.00 (0.99 to 1.01) 1.13 (1.12 to 1.14)
  2010 0.83 (0.82 to 0.83) 1.04 (1.03 to 1.04) 1.17 (1.17 to 1.18)
  2011 0.92 (0.92 to 0.93) 1.11 (1.10 to 1.12) 1.29 (1.28 to 1.30)
  2012 0.96 (0.95 to 0.97) 1.18 (1.16 to 1.19) 1.34 (1.33 to 1.35)
Region
  East Midlands 1.29 (1.28 to 1.30) 1.18 (1.17 to 1.19) 1.07 (1.07 to 1.08)
  East of England 1.18 (1.17 to 1.18) 1.09 (1.09 to 1.10) 1.04 (1.04 to 1.05)
  North East 1.44 (1.42 to 1.45) 1.27 (1.26 to 1.28) 1.20 (1.19 to 1.21)
  North West 1.30 (1.29 to 1.31) 1.18 (1.18 to 1.19) 1.10 (1.10 to 1.11)
  South Central 1.21 (1.20 to 1.22) 1.14 (1.13 to 1.14) 1.10 (1.09 to 1.10)
  South East Coast 1.23 (1.22 to 1.24) 1.12 (1.11 to 1.12) 1.10 (1.10 to 1.11)
  South West 1.43 (1.42 to 1.44) 1.22 (1.22 to 1.23) 1.17 (1.17 to 1.18)
  West Midlands 1.24 (1.24 to 1.25) 1.14 (1.13 to 1.15) 1.08 (1.07 to 1.08)
  Yorkshire and The Humber 1.24 (1.23 to 1.25) 1.08 (1.07 to 1.09) 0.97 (0.96 to 0.97)
  Northern Ireland 1.51 (1.50 to 1.53) 1.55 (1.54 to 1.57) 1.48 (1.47 to 1.49)
  Scotland 1.21 (1.20 to 1.22) 1.22 (1.21 to 1.22) 1.21 (1.20 to 1.22)
  Wales 1.33 (1.32 to 1.34) 1.26 (1.26 to 1.27) 1.22 (1.21 to 1.22)
Chronic kidney disease stage
  1 1.93 (1.76 to 2.11) 2.18 (2.03 to 2.35) 2.05 (1.92 to 2.19)
  2 2.30 (2.21 to 2.40) 1.82 (1.76 to 1.88) 1.93 (1.87 to 1.99)
  3 3.32 (3.25 to 3.40) 1.67 (1.64 to 1.70) 1.48 (1.46 to 1.51)
Continued
 o
n
 4 July 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028062 on 12 June 2019. Downloaded from 
11Feakins B, et al. BMJ Open 2019;9:e028062. doi:10.1136/bmjopen-2018-028062
Open access
strengths and limitations
To date, this is the largest population-based study of 
trends in renal function testing in primary care. The study 
population was an unselected sample of over 4.5 million 
patients from over 600 general practices across the UK 
included in the CPRD database, which has been shown 
to be representative of the UK. The scale and design of 
the study allowed us to test associations adjusted for many 
important potential explanatory and confounding factors. 
Our study has limitations, some of which are inherent in 
the CPRD database. We were not able to ascertain why the 
tests were performed. Even though the CPRD contains 
consultation codes, these provide only a very broad clas-
sification of the time and type of consultation (eg, clinic, 
night visit and home visit). An in-depth analysis of Read 
codes or mining of the consultation free text would be 
required to start to explain the reasons for test ordering, 
which is beyond the scope of this study. Finally, the use 
of the MDRD equation could be challenged. It was the 
formula in use during the period of the study but is now 
considered inferior to the CKD-EPI formula.17 However, 
we have used MDRD, because we wanted the analysis to 
reflect the clinical decision made at the time of the study.
relationship to the literature
The rise in the number of patients having serum creat-
inine concentration measurements and the increased 
frequency of testing for those being tested can be inter-
preted in two ways. CKD has gained more attention since 
the incorporation of CKD into the QOF in 2006–2007. 
The establishment of a register in 2006–2007 and its 
subsequent extension has encouraged renal function 
testing to identify those with CKD who may benefit from 
risk factor modification. From the viewpoint of patient 
safety, our results are encouraging and show that, for 
all the therapies we examined, the prescription of drugs 
that are potentially nephrotoxic is associated with more 
frequent monitoring.
Our results could be interpreted in a different light. 
There is little direct evidence that extra testing has 
Characteristic Univariable IRR (95% CI) Minimally adjusted IRR (95% CI) Fully adjusted IRR (95% CI)
  4 4.98 (4.60 to 5.39) 2.61 (2.45 to 2.77) 2.17 (2.05 to 2.30)
  5 3.92 (3.05 to 5.03) 2.37 (1.94 to 2.89) 1.74 (1.45 to 2.09)
Comorbidities
  Atrial fibrillation 3.09 (3.04 to 3.13) 1.00 (0.99 to 1.02)
  Cancer 2.14 (2.12 to 2.17) 1.15 (1.14 to 1.16)
  Diabetes 3.48 (3.45 to 3.51) 1.98 (1.97 to 1.99)
  Heart failure 3.89 (3.83 to 3.95) 1.07 (1.05 to 1.08)
  Hypertension 2.37 (2.37 to 2.38) 1.28 (1.28 to 1.29)
  Ischaemic heart disease 2.76 (2.73 to 2.78) 1.23 (1.23 to 1.24)
  Peripheral vascular disease 2.55 (2.52 to 2.58) 1.20 (1.19 to 1.21)
  Stroke/transient ischaemic attack 2.85 (2.81 to 2.88) 1.14 (1.13 to 1.15)
  Thyroid disease 2.09 (2.07 to 2.11) 1.31 (1.30 to 1.32)
Pharmacotherapies
  ACE inhibitors 3.20 (3.18 to 3.21) 1.41 (1.41 to 1.42)
  ARBs 2.98 (2.96 to 3.00) 1.25 (1.24 to 1.26)
  Amiodarone/dronedarone 3.49 (3.41 to 3.56) 1.15 (1.13 to 1.17)
  Digoxin 3.39 (3.34 to 3.44) 1.17 (1.16 to 1.19)
  Diuretics 3.27 (3.25 to 3.28) 1.46 (1.46 to 1.47)
  Ethambutol 1.37 (1.09 to 1.73) 1.16 (0.97 to 1.40)
  Gold 11.11 (9.59 to 12.88) 5.48 (4.95 to 6.07)
  Immunosuppressants (not 
including methotrexate)
5.06 (4.97 to 5.15) 3.44 (3.40 to 3.49)
  Lithium 4.14 (4.00 to 4.28) 4.42 (4.32 to 4.52)
  Mesalazine 2.44 (2.37 to 2.50) 2.23 (2.19 to 2.28)
  Methotrexate 9.41 (9.19 to 9.64) 6.17 (6.07 to 6.28)
  NSAIDs 1.55 (1.55 to 1.56) 1.25 (1.25 to 1.25)
  Oral anticoagulants
  
2.93 (2.89 to 2.96) 1.17 (1.16 to 1.18)
IRR, incidence rate ratio; NSAIDs, non-steroidal anti-inflammatory drugs.
Table 2 Continued 
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improved outcomes in the short term or long term.26 
Additional testing has increased the apparent prevalence 
of CKD from 0.12% to 6.51%, but as yet, there has been no 
change in long-term outcomes, such as patients requiring 
renal replacement therapy.27 28 Increases in consultations 
with general practitioners or practice nurses for either 
newly diagnosed disease or monitoring, with associated 
laboratory tests, place further strain on limited healthcare 
resources and increase expenditure. The very substan-
tial costs of renal replacement therapy or cardiovascular 
complications28 mean that testing might be cost-effective, 
even if it results in only modest reductions in the number 
of patients who progress to this stage, but whether this is 
the case is unclear. In a report from one NHS trust in the 
period following the introduction of renal QOF, there was 
an abrupt 61% increase in the number of new referrals 
to nephrology, 54% of which were classified as inappro-
priate and a further 22% as inadequate.29 Inappropriate 
referrals use up resources and may cause unnecessary 
distress to patients and their carers.30
Implications for practice
Rates of testing have increased over the observation period 
in our study. Much of these increases appear to be driven 
by financial incentivisation schemes, such as the QOF. 
However, the increases were found to be independent of 
comorbidities, age and prescriptions for ‘high risk’ drugs. 
Much of the increase in testing appears to have occurred 
in patients with mildly to moderately impaired kidney 
function (CKD stages 2–3). However, there is limited 
evidence to suggest any benefit from interventions deliv-
ered in the early stages of CKD.31 Moreover, studies in 
cholesterol monitoring have shown that more frequent 
testing can have negative consequences,32 particularly for 
biomarkers that have high within-person variability, such 
as serum creatinine,33 with an increased likelihood of 
raising false alarms for increased CKD severity. Hence, a 
more targeted approach could prove beneficial for most 
patients.
Increases in testing are also likely to have knock-on 
effects to other aspects of healthcare, including the finan-
cial burden on the NHS, the time burden on general 
practitioners and laboratory workloads, potentially 
resulting in delayed or missed diagnosis.34 Reducing 
the amount of serum creatinine testing performed as 
part of kidney function monitoring could ease some of 
these burdens, although we acknowledge that a reason-
able amount of serum creatinine testing is performed as 
part of test batches not directly related to the assessment 
of kidney function and including other tests such as full 
blood counts.35
COnClusIOn
The observed increase in kidney function testing could 
be attributable to any or all of several changes that have 
occurred over the period of the study. The introduction 
of pay-for-performance indicators, the establishment 
of a CKD register, national guidelines promoting moni-
toring of renal function in high-risk groups and linkage 
of pathology laboratories to practice systems have poten-
tially all raised the profile of CKD in primary care and 
contributed to the observed increases in testing. While 
it is clear that these initiatives have changed process 
measures, it is still not clear whether clinical outcomes 
have improved as a consequence.
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